

November 05, 2019

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

NSE Symbol: PANACEABIO

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

BSE Scrip Code: 531349

Reg.: Board Meeting on November 14, 2019 for approving the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended September 30, 2019

Dear Sir,

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), this is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, November 14, 2019 at New Delhi, inter-alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended September 30, 2019.

Further, pursuant to Regulations 46(2) & 47(1) of the SEBI LODR Regulations, notice of the said meeting is also being sent for publication in newspapers and uploaded on the website of the Company.

Further, with reference to our earlier announcement dated September 28, 2019 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct for Prevention of Insider Trading under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all Designated Persons of the Company and Material Subsidiaries of the Company till November 16, 2019.

This is for your kind information and record please.

Thanking you, Sincerely yours, for **Panacea Biotec Limited**

Devender Gupta

Chief Financial Officer and Head IT